You are here: Knowledge Bank Press Releases

Press Releases

Press Releases is unique and effective promotional tool offered from aimed at bringing our client’s business message into limelight and more importantly make it reach their target audience. This feature can be utilized to launch new product, promoting existing Pharma product, publish business agreements, annual reports, financial results, corporate performances, important announcements or any important information that has to be conveyed to the target audience.

To add free press releases please click here.

FDA Psychopharmacologic Drug Advisory Committee Supports the Effectiveness of Brintellix® (vortioxetine) in Treating Certain Aspects of Cognitive Dysfunction in Major Depressive Disorder (MDD)

E-mail Print PDF

•    The panel voted 8-2 that substantial evidence has been presented to support a claim of effectiveness for Brintellix for treating certain aspects of cognitive dysfunction in MDD

•    The panel discussed that cognitive dysfunction in MDD represents an appropriate drug development target

Changes to the Roche Corporate Executive Committee

E-mail Print PDF

Silvia Ayyoubi (62), Head of Group Human Resources for Roche and member of the Corporate Executive Committee has decided to retire from Roche following the Annual General Meeting in March 2016. Silvia Ayyoubi joined Roche in 1987 and held several positions of growing responsibility in human resources. She has been Head of Group Human Resources and a member of the Corporate Executive Committee since March 2008.

American Diabetes Association® Survey Shows Summer Camp Can Positively Impact Children's Disease Management Skills, Confidence And Stress Lilly Diabetes commits $93,000 to support Association "Camperships"

E-mail Print PDF

A three-year survey by the American Diabetes Association (Association) shows attending summer camp can do much more than lift the spirits of children with type 1 diabetes. Surveys conducted with caregivers before and after their child attended an Association camp found the experience can increase some children's diabetes knowledge, self-confidence, diabetes management and emotional well-being while enjoying traditional camp activities.

Bristol-Myers Squibb and Pfizer Sign Collaboration with Portola Pharmaceuticals to Develop and Commercialize Investigational Andexanet Alfa in Japan

E-mail Print PDF

Bristol-Myers Squibb Company (NYSE:BMY) and Pfizer Inc. (NSYE:PFE) today announced that the companies have entered into a collaboration agreement with Portola Pharmaceuticals Inc. (Nasdaq: PTLA) to develop and commercialize the investigational agent andexanet alfa in Japan. Andexanet alfa, which is in Phase 3
clinical development in the U.S. and Europe, is designed to reverse the anticoagulant activity of Factor Xa inhibitors, including Eliquis (apixaban).

Bristol-Myers Squibb Foundation Awards Eight Grants Totaling Nearly $11.5M to Make Lung and Skin Cancer Screening, Care More Accessible in High-Risk U.S. Communities

E-mail Print PDF

"The grant from the Bristol-Myers Squibb Foundation will allow us the opportunity to better reach and inform these at-risk patients in our area and surrounding Maryland counties about the need for lung cancer screening while providing desperately needed education and resources for smoking cessation."

U.S. Food And Drug Administration Approves Humulin® R U-500 KwikPen®

E-mail Print PDF

The U.S. Food and Drug Administration (FDA) has approved Eli Lilly and Company's (NYSE: LLY) Humulin® R U-500 KwikPen®(insulin human injection) 500 units/mL, a pre-filled device containing Humulin R U-500, a highly concentrated formulation of insulin. Humulin R U-500 is the only FDA-approved insulin that is five-times more concentrated than standard U-100 insulin. This insulin is used to treat high blood sugar in people with type 1 and type 2 diabetes who need more than 200 units of insulin per day. The safety and efficacy of Humulin R U-500 used in combination with other insulins or delivered by an insulin infusion pump has not been determined.

U.S. FDA Accepts Filing Of Cardiovascular Outcomes Data For Jardiance® (Empagliflozin)

E-mail Print PDF

The U.S. Food and Drug Administration (FDA) accepted a supplemental New Drug Application for Jardiance® (empagliflozin) based on cardiovascular risk reduction data from the landmark EMPA-REG OUTCOME® trial. Boehringer Ingelheim and Eli Lilly and Company (NYSE: LLY) expect to receive a decision from the FDA within the standard review time frame.

Lilly And Roche Diagnostics To Collaborate On Alzheimer's Disease Adjunct Diagnostic ToolEli Lilly and Company (NYSE: LLY) today announced an arrangement to partner with Roche Diagnostics on its ongoing development of a commercially scalable cerebrospinal

E-mail Print PDF

Eli Lilly and Company (NYSE: LLY) today announced an arrangement to partner with Roche Diagnostics on its ongoing development of a commercially scalable cerebrospinal fluid assay for amyloid-beta 1-42.

Bristol-Myers Squibb’s Opdivo (nivolumab) + Yervoy (ipilimumab) Regimen Receives Expanded FDA Approval in Unresectable or Metastatic Melanoma Across BRAF Status1

E-mail Print PDF

Announcement in the U.S. that Food and Drug Administration (FDA) has approved Opdivo (nivolumab) in combination with Yervoy (ipilimumab) for the treatment of patients with BRAF V600 wild-type and BRAF V600 mutation-positive unresectable or metastatic melanoma.1 This indication is approved under accelerated approval based on progression-free survival (PFS).1 Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials.1 This approval expands the original indication for the Opdivo + Yervoy Regimen for the treatment of patients with BRAF V600 wild-type unresectable or metastatic melanoma to include patients, regardless of BRAF mutational status, based on data from the Phase 3 CheckMate -067 trial, in which PFS and overall survival (OS) were co-primary endpoints.

Nutrition and health bars expand market share by tying into wellness, athleticism

E-mail Print PDF

Nutrition and health bars are stealing market share from the category leading snack and cereal bars in part because they tie into the health and wellness trend dominating many consumers’ purchasing decisions in a way snack and cereal bars don’t, according to research analysis from Synergy Flavors.

Page 1 of 78

  • «
  •  Start 
  •  Prev 
  •  1 
  •  2 
  •  3 
  •  4 
  •  5 
  •  6 
  •  7 
  •  8 
  •  9 
  •  10 
  •  Next 
  •  End 
  • »